J&J (NYSE:JNJ): Stelara down 62% but revenue up 10% in Q1 2026. Full investor profile on the $100B healthcare giant, pipeline, dividend streak and key risks.

Key Highlights

• Stelara Is Falling but J&J Is Not: Despite Stelara sales crashing 62% in Q1 2026, J&J grew total revenues nearly 10% to $24.1 billion, driven by 10 double-digit-growing brands across oncology and immunology, proving the depth of its portfolio.
• The $100 Billion Milestone Is in Sight: J&J raised full-year 2026 revenue guidance to $100.8 billion at the midpoint, positioning the company to cross the $100 billion annual revenue threshold for the first time in its 140-year history.
• Sixty-Plus Years of Dividend Growth: With more than 60 consecutive years of dividend increases, AAA-rated balance sheet, and free cash flow consistently above $20 billion annually, J&J remains one of the most reliable income stocks in the S&P 500.

Johnson & Johnson is one of the largest and most diversified healthcare companies in the world. Headquartered in New Brunswick, New Jersey, the company now operates as a focused pharmaceutical and medical devices enterprise following the 2023 spinoff of Kenvue Inc., which took with it the Consumer Health business (including iconic brands such as Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno, and Johnson's Baby). Post-spin, Johnson & Johnson's two reporting segments are Innovative Medicine (pharmaceuticals) and MedTech (medical devices and diagnostics).

Innovative Medicine has been J&J's largest and most profitable business for many years, anchored by blockbuster therapies across immunology, oncology, neuroscience, infectious disease, pulmonary hypertension, and cardiovascular/metabolism. MedTech spans orthopedics, surgical robotics, interventional solutions (cardiovascular and neurovascular), and vision care. Both segments are sizeable multi-billion dollar businesses with leadership positions in their respective therapeutic and procedural categories.

For investors, Johnson & Johnson is a blue-chip dividend aristocrat with more than sixty consecutive years of dividend increases, one of the longest streaks in the S&P 500. It is a defensive holding in most portfolios, offering exposure to secular healthcare demand, an innovation engine supported by substantial research and development investment, and a disciplined capital allocation program that balances dividends, share repurchases, internal R&D, and selective acquisitions. Risks include patent expirations on key drugs (notably Stelara, a major immunology franchise facing biosimilar competition), litigation tail (talc and opioid-related litigation has consumed significant management attention and cash over the past decade), and pricing pressure from U.S. drug pricing reform and international price controls.

Company History

Johnson & Johnson was founded in 1886 by brothers Robert Wood, James Wood, and Edward Mead Johnson in New Brunswick, New Jersey, initially producing ready-to-use sterile surgical dressings based on Joseph Lister's germ theory. The company pioneered mass-production of sterile bandages, maternity kits, and dental floss in the late nineteenth century and progressively expanded into consumer personal care, prescription pharmaceuticals, and medical devices over more than a century of growth.

Notable acquisitions in the modern era include Janssen Pharmaceutica (1961, now the core of Innovative Medicine), LifeScan (diabetes care, later divested), DePuy (orthopedics, 1998), Centocor (biologics, 1999), Pfizer Consumer Healthcare (2006), Synthes (orthopedics, 2012), Actelion (pulmonary hypertension, 2017), and Abiomed (heart pumps, 2022). Divestitures have included diabetes care businesses, LifeScan, and the 2023 Kenvue consumer health spinoff.

Johnson & Johnson has been led historically by internal promotions, with CEOs serving long tenures. Alex Gorsky led the company from 2012 to 2022, overseeing significant portfolio transformation. Joaquin Duato became CEO in January 2022 and has overseen the Kenvue separation, the Abiomed acquisition, and the sharpening of the remaining enterprise around pharmaceuticals and devices.

Business Segments

Innovative Medicine

Innovative Medicine (formerly Janssen Pharmaceuticals) is Johnson & Johnson's pharmaceutical business. Its portfolio spans six therapeutic areas: Immunology (Stelara and Tremfya for psoriasis, psoriatic arthritis, inflammatory bowel disease, and related indications; Simponi; Remicade, the latter largely off-patent); Oncology (Darzalex for multiple myeloma, Erleada for prostate cancer, Imbruvica for certain blood cancers, Carvykti CAR-T cell therapy, Rybrevant for non-small-cell lung cancer); Neuroscience (Spravato for treatment-resistant depression, Invega and Risperdal long-acting injectables for schizophrenia); Pulmonary Hypertension (Opsumit, Uptravi); Cardiovascular and Metabolism (Xarelto anti-coagulant co-marketed with Bayer, Invokana for type 2 diabetes); and Infectious Diseases and Vaccines (Edurant HIV medication, Prezista, Symtuza; the J&J COVID-19 vaccine was discontinued post-pandemic).

Stelara is the largest single franchise and is facing biosimilar competition from 2024 onward in major markets. Johnson & Johnson's strategy is to mitigate the Stelara cliff through uptake of Tremfya (in immunology) and continued growth across oncology, where multiple oncology franchises are growing rapidly. The pharmaceutical pipeline, one of the deepest in the industry, includes late-stage assets across oncology, immunology, and neuroscience that management believes will support continued growth.

MedTech

MedTech covers orthopedics (DePuy Synthes, one of the largest orthopedic franchises in the world, spanning hips, knees, spine, trauma, and extremities), Surgery (energy devices, endomechanical, biosurgery, sutures, and robotics, including the Ottava surgical robot under development), Vision Care (Acuvue contact lenses and surgical ophthalmology), and Interventional Solutions (Biosense Webster electrophysiology, Cerenovus neurovascular, and Abiomed heart pumps). MedTech growth accelerated post-pandemic as elective procedure volumes recovered, and innovation in robotics, electrophysiology, and structural heart is expected to be long-term revenue driver.

Financial Profile

Post-Kenvue spin, Johnson & Johnson's continuing-operations revenue has grown beyond the eighty-to-ninety billion dollar range, reaching $94.2 billion in full year 2025 (up 6% year over year) with full year 2026 guidance raised to $100.8 billion at the midpoint, split between Innovative Medicine (roughly sixty percent) and MedTech (roughly forty percent).

Research and development spending is one of the largest in healthcare in absolute dollars and as a percentage of revenue, funding a pipeline across both segments. Selling, general, and administrative expenses support a significant global sales force across pharmaceuticals and devices, along with investment in direct-to-consumer and medical education.

Free cash flow is substantial, typically north of twenty billion dollars annually in recent years, supporting the dividend, buybacks, tuck-in acquisitions, and litigation settlements. The dividend has been raised every year for more than six decades, one of only a handful of companies with that long a streak. Share repurchases are opportunistic, scaled to available cash after other priorities.

The balance sheet is AAA-rated or near it (one of only two U.S. industrials with triple-A credit ratings, the other being Microsoft, though ratings can migrate). Substantial cash and investments provide flexibility; gross debt is moderate and well-laddered.

Valuation metrics include forward P/E, EV/EBITDA, price-to-free-cash-flow, and dividend yield. Johnson & Johnson typically trades at a modest premium to the broader market reflecting quality and stability, though at a discount to pure-play high-growth biotech peers.

Competitive Position

In Innovative Medicine, J&J competes across therapeutic areas against AbbVie (dominant in immunology with Humira, now facing biosimilars, and Skyrizi and Rinvoq), Eli Lilly (fast-growing in GLP-1 and oncology), Merck (oncology leader with Keytruda and a broad vaccine franchise), Pfizer (broad portfolio including oncology, cardiovascular, and former COVID revenue), Bristol Myers Squibb (oncology), Novartis, Roche, AstraZeneca, GSK, and Sanofi. Each franchise has specific competitors in its therapeutic area.

In MedTech, J&J competes with Medtronic (the largest pure-play medical device company), Stryker (orthopedics, medical-surgical, neurotechnology), Abbott (devices, diagnostics, nutrition), Boston Scientific (interventional and neuromodulation), Zimmer Biomet (orthopedics), Intuitive Surgical (robotic surgery), Edwards Lifesciences (structural heart), Alcon (vision care), and other specialists.

J&J's integrated model across pharmaceuticals and devices was historically considered a diversification advantage, smoothing earnings volatility. Critics argued the conglomerate structure limited focus and discounted valuation; the Kenvue spin was a response to that argument. The remaining company still pairs pharmaceuticals and devices, which has a logic rooted in shared therapeutic area insights, hospital customer overlap, and financial stability.

Key Risks

Patent expiration risk is perennial in pharmaceuticals. Stelara's biosimilar entry is the most immediate concern, with multiple biosimilar entrants receiving regulatory approval in major markets. Management has guided that the impact will be material but partly offset by growth from Tremfya, Darzalex, Erleada, Carvykti, Rybrevant, and newer launches.

Litigation risk has been material at J&J for more than a decade. Thousands of lawsuits alleging asbestos contamination in talcum powder products (including Johnson's Baby Powder) have been ongoing; J&J has attempted multiple settlement structures including subsidiary Chapter 11 filings (the 'Texas two-step' strategy), which have been contested in bankruptcy courts. Opioid-related litigation has been largely addressed through multi-state settlements but residual exposures remain. While these legal liabilities are sizeable, they are generally manageable given J&J's cash flow.

Drug pricing and policy risk has increased materially. The U.S. Inflation Reduction Act grants Medicare the authority to negotiate prices on select high-spend drugs; several J&J drugs have been selected for negotiation, with meaningful revenue implications. International reference pricing and tendering policies continue to pressure ex-U.S. pharmaceutical revenue.

Regulatory risk around FDA approvals, European Medicines Agency decisions, and global drug safety monitoring affects both launch timing and ongoing revenue. MedTech products face their own FDA device-approval processes, post-market surveillance, and product-recall risks.

Pipeline execution risk: with Stelara revenue declining, new product launches and label expansions must successfully deliver to support growth targets. Delays, failed trials, or disappointing commercial uptake would pressure the story.

Management and Governance

Joaquin Duato became CEO in January 2022, following a long career at J&J that included leadership of Janssen (now Innovative Medicine), the global supply chain, and multiple other roles. He has guided the Kenvue spin and sharpened the remaining company's focus. Joseph Wolk serves as CFO. The segment heads for Innovative Medicine and MedTech, along with the heads of R&D, quality, and supply chain, report into Duato.

The board is traditionally composed of directors with healthcare, finance, and public service backgrounds. Governance focus areas include dividend policy (highly watched given the multi-decade streak), capital allocation between R&D and M&A, litigation strategy, and pipeline prioritization.

J&J's Credo, articulated by Robert Wood Johnson II in 1943, is a famous corporate ethics statement prioritizing patients, employees, communities, and then shareholders. The Credo is cited frequently in corporate communications and has been used as a governance anchor across generations of leadership.

Recent Earnings Context

Johnson & Johnson's quarterly earnings reporting is a closely watched event given the breadth of the portfolio. Q1 2026 revenue reached $24.1 billion, up 9.9% year over year, beating analyst estimates of $23.6 billion, fueled by oncology franchise growth (Darzalex, Carvykti, Erleada, and Rybrevant), Tremfya posting 74% growth in immunology, and continued MedTech procedure volume recovery. This performance came despite Stelara sales falling 62% year over year to $656 million on biosimilar competition. Adjusted EPS came in at $2.70, above the consensus estimate of $2.66. Following these results, J&J raised its full year 2026 revenue guidance to $100.8 billion at the midpoint and adjusted EPS guidance to $11.55, positioning the company to cross the $100 billion annual revenue threshold for the first time in its history.

Reported results typically include detailed disclosures by therapeutic franchise within Innovative Medicine and by product category within MedTech, allowing investors to triangulate growth drivers. The company also provides non-GAAP metrics such as operational growth (excluding foreign currency) and adjusted earnings per share.

Management commentary during earnings calls addresses Stelara biosimilar trajectory, pipeline progress, litigation updates, M&A appetite, and capital return plans. The firm's multi-year targets for Innovative Medicine growth (in the mid-single digits) and MedTech growth (in the high-single digits) are recurring anchors of the long-term investment case.

Outlook and Catalysts

Near-term catalysts include quarterly earnings updates on Stelara biosimilar impact, Tremfya uptake, oncology franchise growth (Darzalex, Erleada, Carvykti), MedTech procedure volumes, and pipeline readouts. Key pipeline catalysts include data on new indications and new molecular entities across oncology and immunology.

Longer-term catalysts include commercialization of late-stage assets like nipocalimab (autoimmune), TAR-200 (bladder cancer), and Ottava robotics, along with progression of multi-billion-dollar oncology assets. Litigation resolutions, whether through global settlement or court processes, will also shape investor sentiment.

For investors, J&J is a defensive, dividend-focused healthcare holding with modest but steady growth prospects. Its high credit quality and consistent dividend increases make it a staple of conservative portfolios. Upside to consensus depends on successful navigation of the Stelara patent cliff and multiple pipeline launches; downside risk is relatively contained given the diversification of the business and the strength of the balance sheet.